|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| OPERATING ACTIVITIES | ||||
| Net loss | ||||
| Share-based compensation-product development costs | ||||
| Share-based compensation-selling, general and administrative | ||||
| Share-based compensation-professional fees | ||||
| Share-based compensation included in product development costs, selling, general and administrative expense, professional fees and interest expense | ||||
| Interest expense on lines of credit | ||||
| Interest accretion on loan payable | ||||
| Borrowing costs on loan payable | ||||
| Accrued interest on loan payable | ||||
| Payment of lines of credit interest | ||||
| Accrued interest, borrowing costs and interest accretion on loans payable | ||||
| Non-cash imputed interest expenses | ||||
| Write-off of accounts receivable | ||||
| Unrealized foreign exchange | ||||
| Write-off of accounts payable | ||||
| Loss on settlement of accounts payable | ||||
| Increase in accounts receivable | ||||
| Decrease (increase) in inventory | ||||
| Decrease in prepaid expenses | ||||
| Increase in accounts payable and accrued liabilities | ||||
| Increase in interest payable to related parties | ||||
| Increase in interest payable | ||||
| Net cash used in operating activities | ||||
| Proceeds from lines of credit | ||||
| Proceeds from loan payable | ||||
| Proceeds from promissory notes | ||||
| Proceeds from exercise of warrants | ||||
| Proceeds from sales of ordinary shares | ||||
| Net cash provided by financing activities | ||||
| Effect of foreign exchange on cash | ||||
| Change in cash | ||||
| Cash, beginning of year | ||||
| Cash, end of year | ||||
Loading...
